Here are the 10-K annual reports from BriaCell Therapeutics Corp. Warrant (BCTXZ) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BCTXZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCTXZ filings page.
BriaCell Therapeutics Corp. reported a net loss of $35,325,292 for the year ended July 31, 2026, compared with $26,556,140 for the prior year. Research and development costs were $29,236,508, versus $21,270,678; clinical-trial expenses were $21,787,613, including $16,477,598 for the Bria-IMT pivotal Phase 3 study. Enrollment in that study surpassed 230 patients during fiscal 2026, and the company said it was progressing toward a planned interim analysis.
At July 31, 2026, BriaCell reported working capital of $14,063,292, compared with $15,948,588 a year earlier, and net cash used in operating activities of $28,651,323 versus $28,170,520. Management said it intends to raise additional capital through debt or equity financing and identified substantial doubt about the company’s ability to continue as a going concern. It said there is no assurance funds raised will be sufficient to enable profitable operations or continued operation. Management concluded that disclosure controls and internal control over financial reporting were effective at the reasonable assurance level as of July 31, 2026.